JYONG BIOTECH LTD (MENS) Stock Price & Overview
NASDAQ:MENS • KYG831161065
Current stock price
The current stock price of MENS is 2.15 USD. Today MENS is up by 13.16%. In the past month the price increased by 0.47%.
MENS Key Statistics
- Market Cap
- 163.465M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.06
- Dividend Yield
- N/A
MENS Stock Performance
MENS Stock Chart
MENS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MENS.
MENS Earnings
MENS Forecast & Estimates
MENS Groups
Sector & Classification
MENS Financial Highlights
Over the last trailing twelve months MENS reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 24.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.25% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MENS Ownership
MENS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.66 | 376.832B | ||
| AMGN | AMGEN INC | 15.42 | 188.135B | ||
| GILD | GILEAD SCIENCES INC | 15.77 | 169.255B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.03 | 112.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.53 | 79.215B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.35 | 41.92B | ||
| INSM | INSMED INC | N/A | 33.048B | ||
| BIIB | BIOGEN INC | 11.4 | 27.528B | ||
| NTRA | NATERA INC | N/A | 26.481B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.85 | 25.788B | ||
| MRNA | MODERNA INC | N/A | 19.048B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.372B | ||
| INCY | INCYTE CORP | 12.29 | 17.977B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MENS
Company Profile
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Company Info
IPO: 2025-06-17
JYONG BIOTECH LTD
23F-3, No.95, Section 1, Xintai 5th, Xizhi District
Taipei NEW TAIPEI TW
Employees: 29
Phone: 886227325205
JYONG BIOTECH LTD / MENS FAQ
What does MENS do?
Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. The company is headquartered in Taipei, New Taipei and currently employs 29 full-time employees. The company went IPO on 2025-06-17. The firm is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The firm has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
Can you provide the latest stock price for JYONG BIOTECH LTD?
The current stock price of MENS is 2.15 USD. The price increased by 13.16% in the last trading session.
What is the dividend status of JYONG BIOTECH LTD?
MENS does not pay a dividend.
What is the ChartMill rating of JYONG BIOTECH LTD stock?
MENS has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.